ABPI Suspends Astellas UK
Executive Summary
The UK industry body the Association of the British Pharmaceutical Industry (ABPI) has suspended Astellas UK as a member for one year following serious breaches of its code of practice for the pharmaceutical industry.
You may also be interested in...
AstraZeneca And Genzyme Breach Industry Code Of Practice
AstraZeneca and Genzyme have been named in advertisements for separate breaches of the Association of the British Pharmaceutical Industry's code of practice.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.